Certara, Inc. $CERT is Kopion Asset Management LLC’s 5th Largest Position

Kopion Asset Management LLC lifted its position in Certara, Inc. (NASDAQ:CERT) by 44.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,858,539 shares of the company’s stock after acquiring an additional 570,087 shares during the quarter. Certara accounts for about 7.7% of Kopion Asset Management LLC’s investment portfolio, making the stock its 5th largest holding. Kopion Asset Management LLC’s holdings in Certara were worth $12,173,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in Certara in the 2nd quarter worth approximately $83,000. Finally, Gamco Investors INC. ET AL bought a new stake in Certara in the 4th quarter worth approximately $90,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 4.6%

Shares of CERT stock opened at $7.80 on Wednesday. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock’s 50 day simple moving average is $6.41 and its two-hundred day simple moving average is $6.56. The company has a market cap of $1.21 billion, a PE ratio of -78.00 and a beta of 1.44.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.07 earnings per share. Research analysts predict that Certara, Inc. will post 0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on CERT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. KeyCorp reduced their price target on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, April 13th. Morgan Stanley decreased their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Barclays lowered their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, Stephens dropped their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Certara has an average rating of “Hold” and an average price target of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.